Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;99:2530-2536

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pouplard, C.
Right arrow Articles by Gruel, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pouplard, C.
Right arrow Articles by Gruel, Y.
Related Collections
Right arrow Physiological and pathological control of gene expression
Right arrow CV surgery: coronary artery disease
Right arrow Platelets

(Circulation. 1999;99:2530-2536.)
© 1999 American Heart Association, Inc.


Clinical Investigation and Reports

Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin

Clinical Implications for Heparin-Induced Thrombocytopenia

Claire Pouplard, PhD; Marc-Antoine May, MD; Sophie Iochmann, PhD; Jean Amiral, PhD; Anne-Marie Vissac, MT; Michel Marchand, MD; Yves Gruel, MD

From the Departments of Hematology (C.P., S.I., Y.G.), Anesthesiology (M.A.M.), and Cardiac Surgery (M.M.), Hôpital Trousseau, Tours, and the Department of Immunology (J.A., A.M.V.), Serbio, Gennevilliers, France.

Correspondence to Dr Yves Gruel, MD, Department of Hematology, Hôpital Trousseau, 37044 Tours Cedex, France. E-mail gruel{at}med.univ-tours.fr

Background—Cardiopulmonary bypass (CPB) induces platelet activation with release of platelet factor 4 (PF4), and patients are exposed to high doses of heparin (H). We investigated whether this contributes to the development of antibodies to H-PF4 and heparin-induced thrombocytopenia (HIT).

Methods and Results—CPB was performed with unfractionated heparin (UFH) in 328 patients. After surgery, patients received UFH (calcium heparin, 200 IU · kg-1 · d-1) (group 1, n=157) or low-molecular-weight heparin (LMWH, Dalteparin, 5000 IU once daily) (group 2, n=171). Eight days after surgery, antibodies to H-PF4 were present in 83 patients (25.3%), 46 in group 1 and 37 in group 2 (P=0.12). Most patients (61%) had IgG1 to H-PF4, but only 8 samples with antibodies induced platelet activation with positive results on serotonin release assay. HIT occurred in 6 patients in group 1, but no thrombocytopenia was observed in subjects receiving LMWH, although 2 had high levels of antibodies with positive serotonin release assay results. When antibodies to H-PF4 were present, mean platelet counts were lower only in patients with Fc{gamma}RIIA R/R131 platelets.

Conclusions—These results provide evidence that the development of antibodies to H-PF4 after CPB performed with UFH is not influenced by the postoperative heparin treatment. The antibodies associated with high risk of HIT are mainly IgG1, which is present at high titers in the plasma of patients continuously treated with UFH.


Key Words: cardiopulmonary bypass • heparin • platelets • antibodies




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. E. Warkentin, A. Greinacher, A. Koster, and A. M. Lincoff
Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 340S - 380S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
W. H. Geerts, D. Bergqvist, G. F. Pineo, J. A. Heit, C. M. Samama, M. R. Lassen, and C. W. Colwell
Prevention of Venous Thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 381S - 453S.
[Abstract] [Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
J. Fareed, R. L. Bick, G. Rao, S. Z. Goldhaber, A. Sasahara, H. L. Messmore, D. A. Happensteadt, and A. Nicolaides
The Immunogenic Potential of Generic Version of Low-Molecular-Weight Heparins May Not be the Same as the Branded Products
Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 5 - 7.
[PDF]


Home page
BloodHome page
S. Suvarna, B. Espinasse, R. Qi, R. Lubica, M. Poncz, D. B. Cines, M. R. Wiesner, and G. M. Arepally
Determinants of PF4/heparin immunogenicity
Blood, December 15, 2007; 110(13): 4253 - 4260.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. F. Merry
Focus on Thrombin: Alternative Anticoagulants
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260.
[Abstract] [PDF]


Home page
Am J Health Syst PharmHome page
E. A. Nutescu
Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches
Am. J. Health Syst. Pharm., June 1, 2007; 64(11_Supplement_7): S5 - S13.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
D. C. Kress, S. Aronson, M. L. McDonald, M. I. Malik, A. B. Divgi, A. J. Tector, F. X. Downey III, A. J. Anderson, M. Stone, and C. Clancy
Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes
Ann. Thorac. Surg., May 1, 2007; 83(5): 1737 - 1743.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. M. Everett, R. Yeh, S. Y. Foo, D. Criss, E. M. Van Cott, M. Laposata, E. G. Avery, W. D. Hoffman, J. Walker, D. Torchiana, et al.
Prevalence of Heparin/Platelet Factor 4 Antibodies Before and After Cardiac Surgery
Ann. Thorac. Surg., February 1, 2007; 83(2): 592 - 597.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. E. Warkentin, J.-A. I. Sheppard, C. S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher
Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia
Blood, November 1, 2006; 108(9): 2937 - 2941.
[Abstract] [Full Text] [PDF]


Home page
ICVTSHome page
V. Close, M. Purohit, M. Tanos, and S. Hunter
Should patients post-cardiac surgery be given low molecular weight heparin for deep vein thrombosis prophylaxis?
Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 624 - 629.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
C. Wan, M. Warner, B. DeVarennes, P. Ergina, R. Cecere, and K. Lachapelle
Clinical Presentation, Temporal Relationship, and Outcome in Thirty-Three Patients With Type 2 Heparin-Induced Thrombocytopenia After Cardiotomy
Ann. Thorac. Surg., July 1, 2006; 82(1): 21 - 26.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
E. de Maistre, Y. Gruel, and D. Lasne
Diagnosis and management of heparin-induced thrombocytopenia: [Le diagnostic et le traitement de la thrombopenie induite par l'heparine].
Can J Anesth, June 1, 2006; 53(6_suppl): S123 - S134.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Rauova, L. Zhai, M. A. Kowalska, G. M. Arepally, D. B. Cines, and M. Poncz
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications
Blood, March 15, 2006; 107(6): 2346 - 2353.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. Bennett-Guerrero, T. F. Slaughter, W. D. White, I. J. Welsby, C. S. Greenberg, H. El-Moalem, and T. L. Ortel
Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery
J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1567 - 1572.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. E. Warkentin, R. J. Cook, V. J. Marder, J.-A. I. Sheppard, J. C. Moore, B. I. Eriksson, A. Greinacher, and J. G. Kelton
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin
Blood, December 1, 2005; 106(12): 3791 - 3796.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Martel, J. Lee, and P. S. Wells
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
Blood, October 15, 2005; 106(8): 2710 - 2715.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
A. T. Gurbuz, W. G. Elliott, and A. A. Zia
Heparin-induced thrombocytopenia in the cardiovascular patient: diagnostic and treatment guidelines
Eur. J. Cardiothorac. Surg., January 1, 2005; 27(1): 138 - 149.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Rauova, M. Poncz, S. E. McKenzie, M. P. Reilly, G. Arepally, J. W. Weisel, C. Nagaswami, D. B. Cines, and B. S. Sachais
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia
Blood, January 1, 2005; 105(1): 131 - 138.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Y. Gruel, C. Pouplard, D. Lasne, C. Magdelaine-Beuzelin, C. Charroing, and H. Watier
The homozygous Fc{gamma}RIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes
Blood, November 1, 2004; 104(9): 2791 - 2793.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. E. Warkentin and A. Greinacher
Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 311S - 337S.
[Abstract] [Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
M. Sobel
The Incidence of Heparininduced Thrombocytopenia in Hospitalized Medical Patients Treated With Subcutaneous Unfractionated Heparin: A Prospective Cohort Study
Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2004; 16(2): 147 - 149.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. F. Merry, P. J. Raudkivi, N. G. Middleton, J. M. McDougall, P. Nand, B. P. Mills, B. J. Webber, C. M. Frampton, and H. D. White
Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery
Ann. Thorac. Surg., March 1, 2004; 77(3): 925 - 931.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
U. Harbrecht, B. Bastians, A. Kredteck, P. Hanfland, T. Klockgether, and C. Pohl
Heparin-induced thrombocytopenia in neurologic disease treated with unfractionated heparin
Neurology, February 24, 2004; 62(4): 657 - 659.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. A. Cannon, J. Butterworth, R. D. Riley, and J. M. Hyland
Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery
Ann. Thorac. Surg., February 1, 2004; 77(2): 711 - 713.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
A. Koster and T. Fischer
Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 411 - 416.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. E. Warkentin and A. Greinacher
Heparin-induced thrombocytopenia and cardiac surgery
Ann. Thorac. Surg., December 1, 2003; 76(6): 2121 - 2131.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
T. E. Warkentin, R. S. Roberts, J. Hirsh, and J. G. Kelton
An Improved Definition of Immune Heparin-Induced Thrombocytopenia in Postoperative Orthopedic Patients
Arch Intern Med, November 10, 2003; 163(20): 2518 - 2524.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. E. Warkentin and A. Greinacher
Heparin-induced thrombocytopenia and cardiac surgery
Ann. Thorac. Surg., August 1, 2003; 76(2): 638 - 648.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
E. Pravinkumar and N. R. Webster
HIT/HITT and alternative anticoagulation: current concepts
Br. J. Anaesth., May 1, 2003; 90(5): 676 - 685.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T. E. Warkentin
Pork or beef?
Ann. Thorac. Surg., January 1, 2003; 75(1): 15 - 16.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. L. Francis, G. J. Palmer III, R. Moroose, and A. Drexler
Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery
Ann. Thorac. Surg., January 1, 2003; 75(1): 17 - 22.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. C. Aird and E. J. Mark
Case 15-2002 - A 53-Year-Old Man with a Myocardial Infarct and Thromboses after Coronary-Artery Bypass Grafting
N. Engl. J. Med., May 16, 2002; 346(20): 1562 - 1570.
[Full Text] [PDF]


Home page
BloodHome page
M. P. Reilly, S. M. Taylor, N. K. Hartman, G. M. Arepally, B. S. Sachais, D. B. Cines, M. Poncz, and S. E. McKenzie
Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through Fc{gamma}RIIA
Blood, October 15, 2001; 98(8): 2442 - 2447.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. A. Konkle, T. L. Bauer, G. Arepally, D. B. Cines, M. Poncz, S. McNulty, R. N. Edie, and J. D. Mannion
Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery
Ann. Thorac. Surg., June 1, 2001; 71(6): 1920 - 1924.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
S. R Deitcher and T. L Carman
Heparin-induced thrombocytopenia: natural history, diagnosis, and management
Vascular Medicine, May 1, 2001; 6(2): 113 - 119.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
A. Koster, M. Loebe, R. Sodian, E. V. Potapov, R. Hansen, J. Muller, F. Mertzlufft, G. J. Crystal, H. Kuppe, and R. Hetzer
Heparin antibodies and thromboembolism in heparin-coated and noncoated ventricular assist devices
J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0331 - 335.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. R. McCrae, J. B. Bussel, P. M. Mannucci, G. Remuzzi, and D. B. Cines
Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders
Hematology, January 1, 2001; 2001(1): 282 - 305.
[Abstract] [Full Text] [PDF]